Pharmacogenetics of schizophrenia

American Journal of Medical Genetics - Seminars in Medical Genetics

Volumn 97, Issue 1, 2000, Pages 98-106

  Cichon, Sven ^b   Nöthen, Markus M ^b   Rietschel, Marcella ^b   Propping, Peter ^a  

^a UNIVERSITY OF BONN   (Germany)

^b NONE

Author keywords

Cytochrome P450 enzymes; Dopamine receptors; Pharmacogenomics; Serotonin receptors; SNP

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DIHYDROERGOTAMINE; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; DRUG METABOLIZING ENZYME; KETANSERIN; METHYSERGIDE; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR; SUMATRIPTAN; NEUROTRANSMITTER RECEPTOR; PSYCHOTROPIC AGENT;

DRUG RECEPTOR BINDING; DRUG TARGETING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; FORECASTING; GENETICS; METABOLISM;

CYTOCHROME P-450 ENZYME SYSTEM; FORECASTING; HUMANS; PHENOTYPE; PSYCHOTROPIC DRUGS; RECEPTORS, NEUROTRANSMITTER; SCHIZOPHRENIA;

EID: 0034059097     PISSN: 01487299     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8628(200021)97:1<98::AID-AJMG12>3.0.CO;2-W     Document Type: Review

References (101)

1. Alfaro CL, Lam YW, Simpson J, Ereshefsky L. 1999. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol 19:155-163.
2. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Stehen VM. 1997. Nonfunctional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology 131:174-179.
3. Arinami T, Gao M, Hamaguchi H, Toru M. 1997. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6:577-582.
4. Armstrong M, Daly AK, Blennerhassett R, Ferner N, Idle JR. 1997. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 170:23-26.
5. 2A receptor gone. Lancet 346:281-282.
6. 2A receptor and clinical response to clozapine. Neurosci Lett 217: 177-178.
7. 2A receptor gene and response to clozapine. Mol Psychiatry 3:61-66.
8. 2A receptors and clozapine response. Schizophr Res 32:93-99.
9. Arthur H, Dahl ML, Siwers B, Sjöqvist F. 1995. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 15:211-216.
10. Asghari V, Schoots O, Van Kats S, Ohara K, Jovanovic V, Guan H-C, Bunzow JR, Petronis A, Van Tol HHM. 1994. Dopamine D4 receptor repeat: analysis of different native and mutant forms of the human and rat genes. Mol Pharmacol 46:364-373.
11. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HHM. 1995. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 65:1157-1165.
12. Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA, Potkin SG, Macciardi F, Kennedy JL. 1999. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 21:17-27.
13. 2A) receptor gene in human adult brain. Mol Brain Res 59:90-92.
14. 1A receptor variant with the Ile28Val substitution in the extracellular domain. Naunyn-Schmiedeberg's Arch Pharmacol 356:455-458.
15. 1B receptor. Pharmacogenetics 9:95-102.
16. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Lane CR, Lim EP, Kalayanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES. 1999. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nature Genet 22: 234-238.
17. 4 receptor gene in psychotic patients. Biol Psychiatry 34-459-464.
18. Cichon S, Nöthen MM, Catalano M, Di Bella D, Maier W, Lichtermann D, Minges J, Albus M, Borrmann M, Franzek E, Stöber G, Weigelt B, Körner J, Rietschel M, Propping P. 1995. Identification of two novel polymorphisms and a rare deletion variant in the human dopamine D4 receptor variant. Psychiat Genet 5:97-103.
19. Cohen BM, Ennulat DJ, Centorrino, Matthysse S, Konieczna H, Chu H-M, Cherkerzian S. 1999. Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs. Psychopharmacology 141:6-10.
20. Coutts RT, Urichuk LJ. 1999. Polymorphic cytochromes P450 and drugs used in psychiatry. Cell Mol Neurobiol 19:325-354.
21. Cravchik A, Sibley DR, Gejman PV. 1996. Functional analysis of the human D2 dopamine receptor missense variants. J Biol Chem 271:26013-26017.
22. Cravchik A, Sibley DR, Gejman PV. 1999. Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants. Pharmacogenetics 9:17-23.
23. Cravchik A, Gejman PV. 1999. Functional analysis of the human D5 dopamine receptor missense and nonsense variants: differences in dopamine binding affinities. Pharmacogenetics 9:199-206.
24. Dahl M-L, Bertilsson L. 1993. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 3: 61-70.
25. 1A gene. Am J Med Genet 60: 393-399.
26. 2A) receptor gene: identitication of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet 97:614-619.
27. 7) receptor gene: genomic organization and systematic mutation screening in schizophrenia and bipolar affective disorder. Mol Psychiatry 1:392-397.
28. Evans WE, Relling MV. 1999. Pharmacogenomics: translating fnnctional genomics into rational therapeutics. Science 286:487-491.
29. Fang J, Gorrod JW. 1999. Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. Cell Mol Neurobiol 19:491-510.
30. Feng J, Sobell JL, Heston LL, Cook EH Jr, Goldman D, Sommer SS. 1998. Scanning of the dopamine D and D5 receptor genes by REF in neuropsychiatric patients reveals a novel missense change at a highly conserved amino acid. Am J Med Genet 81:172-178.
31. Frackiewicz EJ, Sramek JJ, Herrera JM, Kurtz NM, Cutler NR. 1997. Ethnicity and antipsychotic response. Ann Pharmacother 31:1360-1369.
32. Friedman E, Adams EF, Hoog A, Gejman PV, Carson E, Larsson C, De Marco L, Werner S, Fahlbusch R. 1994. Normal structural dopamine type 2 receptor gene in prolactin-secrering and other pituitary tumors. J Clin Endocrinol Metab 78:568-574.
33. Gejman PV, Ram A, Gelernter J, Friedman E, Cao Q, Pickar D, Blum K, Noble EP, Kranzler HR, O'Malley S. 1994. No structural mutation in the dopaminc D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. JAMA 271:204-208.
34. Goldman D, Lappalanien J, Ozaki N, Nakhai B, Bergen A, Pesonen U-M, Koulu M, Dean M, Zhang L, Weight F, Eggert M, Virkkunen M, Linnoila M. 1995. Natural structural variants of human serotonin receptors. Psychiatr Genet 5(suppl 1):S22.
35. Halushka MK, Fan J-B, Bentley K, Hsie L, Shen N, Weder A, Cooper R, Lipshutz R, Chakravarti A. 1999. Patterns of single-nucleotide polymorphisms in candidate genes for blood pressure homeostasis. Nature Genet 22:239-247.
36. Hebebrand J, Nöthen MM, Ziegler A, Klug B, Neidt H, Eggermann K, Lehmkuhl G, Poustka F, Schmidt MH, Propping P, Remschmidt H. 1997. Nonreplication of linkage disequilibrium between the dopamine D4 receptor locus and Tourette syndrome. Am J Hum Genet 61:238-239.
37. Housman D, Ledley FD. 1998. Why pharmacogenomics? Why now? Nature Biotechnol 16: 492-493.
38. Itokawa M, Arinami T, Futamura N, Hamaguchi H, Toru M. 1993. A structural polymorphism of human dopamine D2 receptor. D2(Ser311→Cys). Biochem Biophys Res Commun 196:1369-1375.
39. 5A receptor gene in alcoholics and healthy volunteers. Mol Brain Res 58:217-220.
40. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. 1994. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects wth diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459.
41. 2A gene and schizophrenia: relation to phenotype and drug response variability. J Psychiatry Neurosci 24:141-146.
42. Kalow W. 1997. Pharmacogeneties in biological perspective. Pharmacol Rev 49:369-379.
43. Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K, Sieghart W, Aschauer HN, Kasper S. 1998. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 32:101-106.
44. Kato MV, Shimizu T, Nagayoshi M, Kaneko A, Sasaki MS, Ikawi Y. 1996. Genomic imprinting of the human serotonin-receptor (HTR2) gene involved in development of retinoblastoma. Am J Hum Genet 59:1084-1090.
45. Kleyn PW, Vesell ES. 1998. Genetic variation as a guide to drug development. Science 281: 1820-1821.
46. 1A) variant found in a Tourette syndrome patient. Biochem Biophys Res Commun 219: 853-858.
47. 5 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr Genet 2:249-256.
48. 2C). Genomics 2:274-279.
49. Levy G. 1998. Predicting effective drug concentrations for individual patients. Clin Pharmacokinet 34:323-333.
50. 1, (DRD4) gene. Hum Mol Genet 2:767-773.
51. Lin C-H, Tsai S-J, Yu YW-Y, Song H-L, Tu P-C, Sim C-B, Hsu C-P, Yang K-H, Hong C-J. 1999. No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia clozapine response in a Chinese population. NeuroReport 10:57-60.
52. Valine194Glycines is insensitive to dopamine and clozapine: report of a homozygous individual. Am J Med Genet 61:277-282.
53. Llerena A, Cobaleda J, Martinez C, Benitez J, 1996. Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. Eur J Drug Metab Pharmacokinet 21:12-138.
54. Lundstrom K, Turpin M. 1996. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 225:1068-1072.
55. 2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry 153:1092-1094.
56. 23Ser polymorphism. NeuroReport 7:2100-2102.
57. 9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Mol Psychiatry 3:72-75.
58. Marez D, Legrand M, Sabbagb N, Lo Guidice J-M, Spire C, Lafitte J-J, Meyer UA, Broly F. 1997. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193-202.
59. 2A receptor and response to clozapine. Lancet 346:1108.
60. Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, Cola P, Howard A, Badri F, Nöthen MM, Kalow W, Kennedy JL. 1998. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 19:123-132.
61. Masood E. 1999. As consortium plans free SNP map of human genome. Nature 398:545-546.
62. Mihara K, Suzuki A, Kondo T, Yasin N, Furukori H, Nagashima U, Otani K, Kaneko S, Inone Y. 1999. Effects of the CYP2D610 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin Pharmacol Ther 65:291-294.
63. Motulsky AG. 1957. Drug reactions, enzymes, and biochemical genetics. J Am Med Assoc 165:835-837.
64. Nakhai B, Nielsen DA, Linnoila M, Goldman D. 1995. Two naturally occurring amino acid substitutions in the human 5-HTIA receptor: glycine 22 to serine 22 and isoleucine 28 to valine 28. Biochem Biophys Res Commun 210:530-536.
65. Nickerson DA, Taylor SL, Weiss DM, Clark AG, Hutchinson RG, Stengard J, Salomaa V, Vartiainen E, Boerwinkle E, Sing CF. 1998. DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene. Nature Genet 19:233-240.
66. 2 receptor gene locus: association with schizophrenia or treatment response not detected. Psychiat Genet 6:23-27.
67. Nöthen MM, Cichon S, Hemmer S, Hebebrand J, Remschmidt H, Lehmkuhl G, Poustka F, Schmidt M, Catalano M, Fimmers R, Körner J, Rietschel M, Propping P. 1994a. Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity. Hum Mol Genet 3:2207-2212.
68. Nöthen MM, Erdmann J, Shimron-Abarbanell D, Propping P. 1994b. Identitication of genetic variation in the human serotonin 1Dβ receptor gene. Biochem Biophys Res Commun 205:1194-1200.
69. 2A receptor and response to clozapine. Lancet 345:908.
70. Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T, Abe K. 1998. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 32:107-113.
71. 2A receptor influences amplitude and timing of intracellular calcium mobilization. J Neurochem 68:2186-2193.
72. Pan L, Belpaire FM. 1999. In vitro study on the involvement of CYPlA2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. Eur J Clin Pharmacol 55:599-604.
73. Persidis A. 1998. The business of pharmacogenomics. Nature Biotechnol 16:209-210.
74. 7 receptor gene among Finnish alcoholics and controls. Psychiatry Res 77:139-145.
75. Pohjalainen T, Cravchik A, Gejman PV, Rinne J, Nagren K, Syvalathi E, Hietala J. 1997. Antagonist binding characteristics of the Ser311→Cys variant of human dopamine D2 receptor in vivo and in vitro. Biochem Biophys Res Commun 232:143-146.
76. Potkin SG, Shen Y, Pardes H, Phelps BH, Zhou D, Shu L, Korpi E, Wyatt RJ. 1984. Haloperidol concentrations elevated in Chinese patients. Psychiatry Res 12:167-172.
77. Prior TI, Chue PS, Tibbo P, Baker GB. 1999. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 9:301-309.
78. Propping P, Kopun M. 1973. Pharmacogenetic aspects of psychoactive drugs: facts and fancy. Humangenetik 20:291-320.
79. Propping P, Nöthen MM. 1995. Genetic variation of CNS receptors - a new perspective for pharmacogenetics. Pharmacogenetics 5: 318-325.
80. 4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry 51:912-917.
81. Rietschel M, Naber D, Oberländer H, Holzbach R, Fimmers R, Eggermann K, Möller HJ, Propping P, Nöthen MM. 1996. Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology 15:491-496.
82. 2C receptor gene. NeuroReport 8:1999-2003.
83. Rietschel M, Kennedy JL, Macciardi F, Meltzer HY and the Consensus Group for Outcome Measures in Psychoses for Pharmacological Studies. 1999. Application of pharmacogenetics to psychotic disorders: the first consensus conference. Schizophr Res 37:191-196.
84. 3 receptor variant and tardive dyskinesia. Eur Arch Psychiatry Clin Neurosci 250:31-35.
85. 1A receptor. Neuropsychopharmacology 17:18-26.
86. Seeman P, Ulpian C, Chouinard G, Van Tol HHM, Dwosh H, Lieberman JA, Siminovitch K, Liu ISC, Waye J, Voruganti P, Hudson C, Serjeant GR, Masibay AS, Seeman MV. 1994. Dopamine D4 receptor variant, D4Glycine194, in Africans, but not in Caucasians: no association with schizophrenia. Am J Med Genet 54:384-390.
87. 3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 4:247-253.
88. 4 receptor subtypes and response to clozapine. Lancet 341:116.
89. 5 receptor gene and schizophrenia. Hum Genet 97:714-719.
90. Sindrup SH, Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF. 1993. Are poor inctabolizers of sparteine/debrisoquine less pain tolerant than extensive metabolizers? Pain 53:335-339.
91. Sobell JL, Lind TJ, Sigurdson C, Zald DH, Snitz BE, Grove WM, Heston LL, Sommer SS. 1995. The D5 dopamine receptor gene in schizophrenia: identification of a nonsense change and multiple missense changes but lack of association with disease. Hum Mol Genet 4:507-514.
92. 2C receptor gene. NeuroReport 29: 169-172.
93. Spina E, Ancione M, Di Rosa AE, Meduri M, Caputi AP. 1992a. Polymorphic debrisoquine oxidation and acute neuroleptic induced adverse effects. Eur J Clin Pharmacol 42:347-348.
94. Spina E, Sturiale V, Valvo S, Ancione M, Di Rosa AE, Meduri M, Caputi AP. 1992b. Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions. Acta Psychiatr Scand 86:364-366.
95. Spurlock G, Heils A, Holmans P, Williams J, D'Souza UM, Cardno A, Murphy KC, Jones L, Buckland PR, McGuffin P, Lesch KP, Owen MJ. 1998. A family-based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry 3:42-49.
96. Steen VM, Lovlie R, MacEwan T, McCreadie RG. 1997. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 2:139-145.
97. Van Tol HHM, Wu CM, Guan H-C, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V. 1992. Multiple dopamine D4 receptor variants in the human population. Nature 358:149-152.
98. Vogel F. 1959. Moderne Probleme der Humangenetik. Ergebn Inn Med Kinderheilk 12: 52-125.
99. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F. 1999. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Comm 254:628-631.
100. Yasumori T, Chen LS, Li QH, Ueda M, Tsuzuki T, Goldstein JA, Kato R, Ymazoe Y. 1999. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19. Biochem Pharmacol 57:1297-1303.
101. Zenner MT, Nobile M, Henningsen R, Smeraldi E, Civelli O, Hartman DS, Catalano M. 1998. Expression and characterization of a dopamine D4R variant associated with delusional disorder. FEBS Lett 422:146-150.